To the best of our knowledge, this is the first study to perform evaluations of the four PD-L1 antibodies in ESCC, with the largest number of pathologists, coming from multiple centers and possessing diverse clinical practice experience. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.